<DOC>
	<DOCNO>NCT02845297</DOCNO>
	<brief_summary>This multicenter , nonrandomized , open-label phase 2 study ( safety run-in phase ) azacitidine ( AZA ) 75 mg/m2 give IV SQ day 1-7 every 28 day combination pembrolizumab 200 mg give IV every 3 week ( start day 8 cycle 1 ) . The dose/schedule AZA select study FDA approve patient MDS/AML .</brief_summary>
	<brief_title>Phase 2 Study Azacitidine Combination With Pembrolizumab Relapsed/Refractory Acute Myeloid Leukemia ( AML ) Patients Newly Diagnosed Older ( ≥65 Years ) AML Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Cohort # 1 1 . Have histologically cytologically confirm relapsed refractory AML ( i.e . ≥5 % blast manual differential bone marrow aspirate/biopsy/flow cytometry ) , exclude acute promyelocytic leukemia ( APL ; FAB M3 ; ( 15 ; 17 ) ) 2 . Be willing able provide write informed consent/assent trial . 3 . Be &gt; 18 year age day sign informed consent . 4 . Not appropriate candidate intensive salvage chemotherapy due comorbidities disease treatmentrelated factor . NOTE : Subjects receive prior treatment hypomethylating agent either Myelodysplastic Syndrome ( MDS ) , Myeloproliferative Neoplasm ( MPN ) , AML eligible achieve response hypomethylating agent past ( PR CR ) progress receive therapy hypomethylating agent . NOTE : Subjects prior allogeneic stem cell transplant ( alloHSCT ) eligible long least 3 month allogeneic HSCT immune suppression least 3 week ( &gt; 21 day ) evidence active graft versus host disease ( GVHD ) . Subjects prior alloHSCT NOT eligible enrollment safety run phase . 5 . Demonstrate adequate organ function define Table 1 , screen lab perform within 14 day treatment initiation . 6 . ECOG performance status ≤ 2 . 7 . A projected life expectancy least 12 week . 8 . Female subject childbearing potential negative urine serum pregnancy within 72 hour prior receive first dose study medication . If urine test positive confirm negative , serum pregnancy test require . 9 . Female subject childbearing potential ( Section 5.8.2 ) must willing use adequate method contraception outline Section 5.8.2 Contraception , course study 120 day last dose study medication . Note : Abstinence acceptable usual lifestyle prefer contraception subject . 10 . Male subject childbearing potential ( Section 5.8.2 ) must agree use adequate method contraception outline Section 5.8.2 Contraception , start first dose study therapy 120 day last dose study therapy . Note : Abstinence acceptable usual lifestyle prefer contraception subject . 11 . As determined enrol physician protocol designee , ability patient understand comply study procedure entire length study . Cohort # 2 1 . Have histologically cytologically confirm newly diagnose AML ( i.e . ≥ 20 % blast manual differential bone marrow aspirate/biopsy and/or peripheral blood ) , exclude acute promyelocytic leukemia ( APL ; FAB M3 , ( 15 ; 17 ) ) 2 . Be willing able provide write informed consent/assent trial . 3 . Be ≥65 year age day sign informed consent . 4 . Have receive NO prior treatment AML exception hydroxyurea/leukapheresis . NOTE : Subjects may treat preexistent myeloid disorder Myelodysplastic Syndrome Myeloproliferative Neoplasm exclude hypomethylating agent . 5 . Demonstrate adequate organ function define Table 1 , screen lab perform within 14 day treatment initiation . 6 . ECOG performance status ≤ 2 . 7 . A projected life expectancy least 12 week . 8 . Female subject childbearing potential negative urine serum pregnancy within 72 hour prior receive first dose study medication . If urine test positive confirm negative , serum pregnancy test require . 9 . Female subject childbearing potential ( Section 5.8.2 ) must willing use adequate method contraception outline Section 5.8.2 Contraception , course study 120 day last dose study medication . Note : Abstinence acceptable usual lifestyle prefer contraception subject . 10 . Male subject childbearing potential ( Section 5.8.2 ) must agree use adequate method contraception outline Section 5.8.2 Contraception , start first dose study therapy 120 day last dose study therapy . Note : Abstinence acceptable usual lifestyle prefer contraception subject . 11 . As determined enrol physician protocol designee , ability patient understand comply study procedure entire length study . Adequate Organ Function Laboratory Values White blood cell ( WBC ) count &lt; 30,000 /mcL Serum creatinine OR Measured calculate creatinine clearance ( GFR also use place creatinine CrCl ) ≤1.5 X upper limit normal ( ULN ) OR ≥60 mL/min subject creatinine level &gt; 1.5 X institutional ULN Serum total bilirubin ≤ 1.5 X ULN* AST ( SGOT ) ALT ( SGPT ) ≤ 3 X ULN Albumin &gt; 2.5 mg/dL International Normalized Ratio ( INR ) Prothrombin Time ( PT ) Activated Partial Thromboplastin Time ( aPTT ) ≤1.5 X ULN unless subject receive anticoagulant therapy long PT PTT within therapeutic range intend use anticoagulant ≤1.5 X ULN unless subject receive anticoagulant therapy long PT PTT within therapeutic range intend use anticoagulant Cohort # 1 1 . Is currently participate receive study therapy participate study investigational agent receive study therapy use investigational device within 4 week first dose treatment . NOTE : Subjects treat clinical study allogeneic stem cell transplant ( alloHSCT ) eligible least 3 month allogeneic HCT least 3 week ( &gt; 21 day ) immune suppression evidence active GVHD ( physiologic corticosteroid replacement therapy adrenal pituitary insufficiency allow ) . Subjects prior alloHSCT eligible enrollment safety run phase . 2 . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment . 3 . Has know history active TB ( Bacillus Tuberculosis ) 4 . Hypersensitivity pembrolizumab excipients . 5 . Has prior anticancer monoclonal antibody ( mAb ) within 4 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due agent administer 4 week earlier . 6 . Has prior chemotherapy , target small molecule therapy , radiation therapy within 2 week growth factor within 1 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due previously administer agent . Note : Subjects ≤ Grade 2 neuropathy exception criterion may qualify study . Note : If subject receive major surgery , must recover adequately toxicity and/or complication intervention prior start therapy . 7 . Has know additional malignancy progress require active treatment . Exceptions include basal cell carcinoma skin squamous cell carcinoma skin undergone potentially curative therapy situ cervical cancer . 8 . Has know active central nervous system ( CNS ) leukemia . Subjects previously treat CNS leukemia may participate provide documented clearance CNS leukemia actively treat intrathecal chemotherapy . 9 . Has active autoimmune disease require systemic treatment past 2 year ( i.e . use disease modify agent , corticosteroid immunosuppressive drug ) . Replacement therapy ( eg. , thyroxine , insulin , physiologic corticosteroid replacement therapy adrenal pituitary insufficiency , etc . ) consider form systemic treatment . Subjects require intermittent use bronchodilator local steroid injection exclude study . 10 . Has know history , evidence active , noninfectious pneumonitis . 11 . Has active uncontrolled infection require systemic therapy ( viral , bacterial fungal ) . Patients infection active treatment control antibiotic eligible . 12 . Has white blood cell count &gt; 30 x 109/L . NOTE : Leukapheresis Hydroxyurea permit meet criterion stop ≥12 hour start treatment study . 13 . Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . 14 . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial . 15 . Is pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment . 16 . Has receive prior therapy antiPD1 , antiPDL1 , antiPDL2 agent . 17 . Has know history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) . 18 . Has know active Hepatitis B ( e.g. , HBsAg reactive ) Hepatitis C ( e.g. , HCV RNA [ qualitative ] detect ) . 19 . Has receive live vaccine within 30 day plan start study therapy . Note : Seasonal influenza vaccine injection generally inactivate flu vaccine allow ; however intranasal influenza vaccine ( e.g. , FluMist® ) live attenuate vaccine , allow . Cohort # 2 1 . Has receive treatment hypomethylating agent preexistent myeloid disorder Myelodysplastic Syndrome ( MDS ) Myeloproliferative Neoplasm ( MPN ) . 2 . Is currently participate receive study therapy participate study investigational agent receive study therapy use investigational device within 4 week first dose treatment preexistent myeloid disorder MDS MPN . 3 . Not eligible treatment standard cytarabine anthracycline similar intensive induction chemotherapy due comorbidities factor , unwilling receive intensive induction therapy . 4 . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment . 5 . Has know history active TB ( Bacillus Tuberculosis ) 6 . Hypersensitivity pembrolizumab excipients . 7 . Has prior anticancer monoclonal antibody ( mAb ) within 4 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due agent administer 4 week earlier . 8 . Has prior chemotherapy , target small molecule therapy , radiation therapy within 2 week growth factor within 1 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due previously administer agent . Note : Subjects ≤ Grade 2 neuropathy exception criterion may qualify study . Note : If subject receive major surgery , must recover adequately toxicity and/or complication intervention prior start therapy . 9 . Has know additional malignancy progress require active treatment . Exceptions include basal cell carcinoma skin squamous cell carcinoma skin undergone potentially curative therapy situ cervical cancer . 10 . Has know active central nervous system ( CNS ) leukemia . Subjects previously treat CNS leukemia may participate provide documented clearance CNS leukemia actively treat intrathecal chemotherapy . 11 . Has active autoimmune disease require systemic treatment past 2 year ( i.e . use disease modify agent , corticosteroid immunosuppressive drug ) . Replacement therapy ( eg. , thyroxine , insulin , physiologic corticosteroid replacement therapy adrenal pituitary insufficiency , etc . ) consider form systemic treatment . Subjects require intermittent use bronchodilator local steroid injection exclude study . 12 . Has know history , evidence active , noninfectious pneumonitis . 13 . Has active uncontrolled infection require systemic therapy ( viral , bacterial fungal ) . Patients infection active treatment control antibiotic eligible . 14 . Has white blood cell count &gt; 30 x 109/L . NOTE : Leukapheresis hydroxyurea permit meet criterion stop ≥12 hour start treatment study . 15 . Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . 16 . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial . 17 . Is pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment . 18 . Has receive prior therapy antiPD1 , antiPDL1 , antiPDL2 agent . 19 . Has know history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) . 20 . Has know active Hepatitis B ( e.g. , HBsAg reactive ) Hepatitis C ( e.g. , HCV RNA [ qualitative ] detect ) . 21 . Has receive live vaccine within 30 day plan start study therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>